v3.26.1
Segment Information - Schedule of Consolidated Net Loss (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Significant segment expenses    
General and administrative $ 6,212,329 $ 850,282
Research and development 321,271
Professional fees - Other 2,978,689 736,686
Interest expense 1,615 553,937
Impairment expense 2,045,253
Other segment items (16,307) (10,664)
Total operating and segment expenses 11,542,850 2,130,241
Reconciliation of net loss    
Change in fair value of warrant liabilities 2,314,353 (13,515)
Consolidated net loss 13,857,203 2,116,726
Biotech [Member]    
Significant segment expenses    
General and administrative 6,088,082 850,282
Research and development 321,271
Professional fees - Other 2,770,181 736,686
Interest expense 1,615 553,937
Impairment expense 2,045,253
Other segment items (16,307) (10,664)
Total operating and segment expenses 11,210,095 $ 2,130,241
Mining [Member]    
Significant segment expenses    
General and administrative 124,247  
Research and development  
Professional fees - Other 208,508  
Interest expense  
Impairment expense  
Other segment items  
Total operating and segment expenses $ 332,755